¹⁶¹Tb-PSMA – Next-Generation Cancer Treatment Starts Here!
Terbium-161 (Tb-161) represents a breakthrough in targeted radioligand therapy, offering a dual-action mechanism that delivers unparalleled precision and efficacy in treating cancer. Emitting both beta particles and highly potent Auger electrons, Tb-161 uniquely targets cancer cells at the single-cell level—especially micro metastases—while sparing surrounding healthy tissues.
Harnessing the Power of Auger Electrons
Terbium-161 emits Auger electrons, which are low-energy electrons that produce high linear energy transfer near their emission site. This results in substantial damage to cancer cells at the DNA level when delivered inside or adjacent to the cell nucleus, while sparing surrounding healthy tissues. Auger electrons create ultra-precise, short-range molecular interactions, maximizing tumor targeting while minimizing surrounding tissue damage.
Clinical Validation: A Global First
Isotopia’s Tb-161 is the focus of the world’s first Phase I/II clinical trial, named the VIOLET study, evaluating [¹⁶¹Tb]-Tb-PSMA-I&T in metastatic castration-resistant prostate cancer (mCRPC).
- No dose-limiting toxicities observed
- Safe and well-tolerated up to 7.4 GBq while gradually evaluating safety up to 9.5 GBq
- Establishes Tb-161 as a promising next-generation Radioligand therapeutic (RLT)
Built for Global Scalability and Trust
- GMP Production: In the final stages of GMP certification
- Sterile & Safe: Tb-161 produced under stringent sterile conditions; safety validated through clinical data
- Secured Supply Chain: Long-term agreements for Gadolinium-160 (Gd-160) and priority reactor access
- Global Footprint: Operating from Israel with new production facilities and launching soon in the USA
Tb-161's Unique Advantages:
- Enhanced Emission: Extra Auger and conversion electrons for improved therapy
- Micro-metastases Targeting: Effective against small tumor clusters
- Versatile Applications: Suitable for NETs (Neuroendocrine tumors), prostate and other cancers
- Dual Benefit: Enables both effective therapy and high-quality SPECT imaging
- Extended Half-life: 6.89 days for flexible scheduling and delivery
Feature |
|---|
Emissions |
Range in Tissue |
Tumor Targeting |
Imaging Capability |
Clinical Stage |
Supply Chain |
Terbium-161 (Tb-161) |
|---|
Beta, Auger, conversion |
Very short (Auger) |
Single cells, micro metastases |
SPECT |
Early-phase trials |
Emerging, scaling up |
Lutetium-177 (Lu-177) |
|---|
Beta, gamma |
Short (beta) |
Larger lesions |
SPECT |
Approved for prostate/NETs |
Established |
Partner with us to redefine the future of Theranostic Oncology
Backed by clinical data, regulatory momentum, and scalable GMP-grade production, Isotopia’s Tb-161 is shaping the next generation of theranostic medicine.
Whether you’re a pharmaceutical company, a radiopharmacy, a research institution, or a distributor, we invite you to join us in advancing innovative oncology care.
If your company has a molecule ready for development, our team is here to support you with dependable, precise labeling solutions—no matter the complexity.
Connect with us today to explore how we can move your innovation forward, together.
